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Introduction: Clinical trials have found that the use of nicotine replacement therapy (NRT) to reduce cigarette
consumption results in signiﬁcant declines in cigarette consumption and increases smokers' propensity to quit.
However, observational “real-world” studies have foundmuch smaller effects. This may be because of low levels
of NRT use. This study examined the association between amount and duration of NRT use amongst those
attempting to reduce their cigarette consumption with motivation to quit and cigarette consumption.
Methods:Data came from 2,158 smokers who took part in the Smoking Toolkit Study. A representative survey of
smokers in England aged 16+.
Results: Only 54.4% of patch users and 32.2% of non-transdermal NRT users reported using NRT with a frequency
that would be expected to substantially inﬂuence cigarette consumption (4+ units per day for acute NRT forms
and at least daily for transdermal patches). Those using the patch at or above this threshold smoked 1.3 cigarettes
per day fewer than those using it below the threshold (p= 0.059), whilst those using non-transdermal NRT at
or above this threshold smoked 0.9 cigarettes less per day (p = 0.022). In both cases, those using NRT more
frequently had greater motivation to quit. Less than 1/5th of participants reported using a combination of NRT
products. Use of NRT long-termwas associated with lower motivation to quit and higher cigarette consumption.
Conclusion: Smokers attempting to reduce their cigarette intake are underusing NRT and this is associated with
cigarette consumption and motivation to quit. These ﬁndings may explain why population-based studies have
failed to report similar ﬁndings to clinical trials.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
The National Institute for Health and Care Excellence (NICE) in the
UK recently released guidance on the use of nicotine replacement
therapy (NRT) to reduce cigarette intake (NICE, 2013). The focus wasth Behaviour Research Centre,
179.
. This is an open access article underpredominantly on the use of NRT for smoking reduction, i.e. attempting
to cut down cigarette consumption without any intention to quit and
use during periods of time when they are unable to smoke, i.e. periods
of temporary abstinence. The UK is currently the only country to have
licensed and recommend that smokers use NRT for these purposes
and, as a consequence, is at the forefront of the debate on dual NRT
and cigarette use.
NICE advocated the use of pharmacology for smoking reduction
and/or temporary abstinence on the basis of clinical trials andthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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ness in relation to promoting smoking cessation amongst those
who are initially unable or unwilling to stop smoking (Beard, Aveyard,
Brown, & West, 2012; Beard, Aveyard, Michie, McNeill, & West, 2013;
Beard, Brown, & Robert, 2014; Beard, Fidler, & West, 2011; Beard,
McNeill, et al., 2011, 2013; Beard&West, 2012;Moore et al., 2009). How-
ever, NICE also acknowledged that any interim reduction in harm was
unlikely. Although randomised controlled trials demonstrate that indi-
viduals who are unmotivated to stop smoking, andwho use NRT concur-
rently with cigarettes, are more likely to report signiﬁcant reductions in
their cigarette consumption (Moore et al., 2009); similar ﬁndings do
not translate to the population level. Smokers in the general population
using NRT for smoking reduction and/or temporary abstinence smoke
more cigarettes than other smokers and report reductions in consump-
tion of only a few cigarettes per day over time (Beard, Aveyard, et al.,
2012; Beard, Aveyard, et al., 2013; Beard, Fidler et al., 2011; Beard,
McNeill, et al., 2011, 2013; Beard & West, 2012; Beard et al., 2014).
One possible reason for the discrepancy between clinical trials and
the “real world” is that at the population level, smokers are not usually
provided with behavioural support or instructions on the use of
medicinal nicotine products. This may result in smokers using NRT sub-
optimally. There is evidence that smokers who are attempting to quit
smoking often use too little medication and for too short a period
(Shiffman, Hughes, Pillitteri, & Burton, 2003; Shiffman et al., 2002). One
reason why smokers' under-dose is that too many of them mistakenly
believe that NRT is unsafe—in fact,many believe that NRT is as dangerous
as cigarettes (Bansal, Cummings, Hyland, & Giovino, 2004). Similarly,
smokers often fail to use combination NRT, which is more effective
than the use of only one NRT product (Brose et al., 2011). Although
single-form NRT provides effective treatment for tobacco dependence,
typically doubling success rates compared with placebo (Stead, Perera,
Bullen, Mant, & Lancaster, 2008); a strategy for further improving its
efﬁcacy is to combine one medication that allows for passive nicotine
delivery (e.g. transdermal nicotine patch), with another medication
that permits ad libitum nicotine consumption (e.g. non-transdermal
products such as the nicotine gum).
It is important to determine whether dual users similarly underuse
NRT andwhether this explains the low effectiveness of NRT for smoking
reduction and/or temporary abstinence at the population level in
relation to reductions in cigarette consumption. Some support for this
hypothesis comes from a 2007 study, where high dosages of NRT were
found to be associated with larger reductions in cigarette consumption,
NNAL and carbon monoxide relative to low doses of NRT amongst
continuing smokers (Hatsukami et al., 2007). Moreover, in a recent qual-
itative study, which assessed smokers' beliefs about and use of NRT for
smoking reduction and/or temporary abstinence, we established that
smokers use combination NRT sequentially rather than concurrently
and that underuse may be due to costs and concerns about overdose
(Beard, Vangeli, Michie, & West, 2012). Of course, such qualitative
studies cannot provide estimates of the prevalence of the phenomena
observed, whilst the ﬁndings by Hatsukami et al. (2007) may not
apply in the real world outside of a clinical setting.
The current study addressed these issues and extended the ﬁndings
using data from the Smoking Toolkit Study, a population-based survey
of adults aged 16+ in England, by assessing amongst those using NRT
for smoking reduction and/or temporary abstinence the association be-
tween combination NRT use, length of NRT use and frequency of NRT
use, with cigarette consumption and motivation to quit. This is a
novel investigation based on the hypothesis that the relationship be-
tween extent of NRT use and effectiveness may be moderated by use
duration. There is evidence that reductions in consumption amongst
those using NRT for smoking reduction subside over time in clinical
trials (Haustein, Batra, Landfeldt, & Westin, 2003; Moore et al., 2009);
possibly as smokers enter a “maintenance phase” and therefore cease
reductions in their cigarette intake, or start to believe that they have
failed to cut down and thus increase their cigarette consumption.Similarly, if it is the case that in the “realworld” thosewhoaremore nic-
otine dependent use NRT longer, one may expect that those using NRT
for extendedperiods of timewill have higher cigarette consumption and
lower odds of a quit attempt due to selection bias.
The ﬁndings from this study will help to inform smoking reduction
interventions, which is vital given that NICE provides little guidance
on how to implement a dual use approach in practice. They will also in-
form policy makers in countries currently considering whether to li-
cence NRT for smoking reduction and/or temporary abstinence and
whether to offer smoking reduction as a tobacco control treatment
within health care services. If it is the case that smokers are underusing
NRT and that greater effectiveness is observed with better use, then in-
terventions should be aimed at encouraging adherence to pharmacolog-
ical therapy. Drug adherence interventions to date have had mixed
efﬁcacy (e.g. Banning, 2009), partially as they have been based on intu-
ition rather than theoretical knowledge. According to the Necessity-
Concerns Framework (Horne & Weinman, 2002), smokers' motivation
to start and persist with medication will be inﬂuenced by the way in
which they judge their personal need for the treatment relative to
their concerns about the potential adverse effects. Interventions should,
as a consequence, emphasise the pros of NRT use, ensure that smokers
hold accurate perceptions about their addiction and understand that
use of pharmacological support is the optimal approach to smoking
reduction. However, if it is the case that the effectiveness of NRT
dissipates over time, such interventions may also constrain pharmaco-
logical support to a given time period.
2. Methods
2.1. Design
The study formed part of the Smoking Toolkit Study (http://www.
smokinginengland.info), an ongoing population study designed to
provide information on smoking and smoking cessation patterns
amongst smokers and recent ex-smokers in England. The Smoking
Toolkit Study involves monthly household surveys using a random
location sampling design, with initial random selection of grouped
output areas (containing 300 households), stratiﬁed by ACORN (socio-
demographic) characteristics (http//www.caci.co.uk/acorn/acornmap.
asp) and region. Interviewers then choose which houses within these
areas are most likely to fulﬁl their quotas and conduct face-to-face
computer-assisted interviews with one member per household.
Further details of which are described elsewhere (Fidler et al., 2011).
Between July 2010 and December 2013, 79,530 adults were sur-
veyed; of whom, 21.8% (n = 17,284) reported that they were current
smokers. Thirteen percent (n = 2,158) of smokers were using NRT.
These form the sample for this study.
2.2. Measures
Current smokers were asked “Are you currently trying to cut down
on how much you smoke but not currently trying to stop?”—(yes; no;
don't know). If they answered “yes” they were asked “Which, if any, of
the following are you currently using to help you cut down the amount
you smoke?—(nicotine patch; nicotine gum; nicotine lozenges/tablets;
nicotine inhaler; nicotine nasal spray; I don't know, none of these;
other). All smokers were asked “Do you regularly use any of the follow-
ing in situations when you are not allowed to smoke?—(nicotine patch;
nicotine gum; nicotine lozenges/tablets; nicotine inhaler; nicotine nasal
spray; I don't know; none of these; other). Those reporting the use of
NRT for smoking reduction and/or temporary abstinence were also
asked “How many times per day on average do you use a nicotine re-
placement product?”—(not every day and less than once per week;
not every day but at least once a week; once per day; twice per day;
3–4 times per day; 5–6 times per day; 7–11 times per day; more than
12 times per day) and “How long have you used nicotine replacement
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weeks up to twelve weeks; more than 12 weeks). Cigarette consump-
tion, motivation to quit and time to ﬁrst cigarette. Motivation to quit
wasmeasured using a dichotomised version of the validatedMotivation
to Stop Scale (MTSS): participants were divided into those whowanted
to quit within the next three months and those who did not (Kotz,
Brown, & West, 2013).2.3. Analysis
For all analyses, R version 2.15.2 was used. We conducted a series of
logistic and linear regression analyseswith combinationNRT use, length
of NRT use and frequency of NRT use as independent variables; and
baseline cigarette consumption per day and proportion of smokers
reporting motivation to quit within the next three months, as depen-
dent variables. Frequency of NRT use was dichotomised according to
clinical guidelines into use that would be expected to produce a signiﬁ-
cant clinical effect (i.e. non-transdermal use of NRT at least 4 times per
day and the use of the nicotine patch at least daily) and use that would
not be expected to produce a signiﬁcant clinical effect (i.e. non-
transdermal use of NRT less than 3 times per day and non-daily use of
the nicotine patch). All analyses were adjusted for age, gender, social
grade and time to ﬁrst cigarette of the day. Associations with cigarette
consumption were also adjusted for recent quit attempts. The reason
being, that those who attempt to quit and relapse are likely to resume
a lower level of smoking (Knoke, Anderson, & Burns, 2006).
To assess the possibility that the association between length of NRT
use with cigarette consumption and motivation to quit may not be
linear, we also ﬁtted separate segmented regression models, allowing
for singular and multiple breakpoints (breakpoints are the values of
the independent variable where the slope of the function changes).
The “segmented package” was used (Muggeo, 2013). This package
adopts an iterative procedure whereby only starting values for the
breakpoints are required (Muggeo, 2003). It also implements bootstrap
restarting tomake the algorithm less sensitive to starting values (Wood,
2001). For reasons of parsimony, only the results of the segmented
regression models are reported if they explained more variance than
the simple linear and logistic equivalents. STROBE guidelines for theNote: NTP=Non-Transdermal Product e.g. ni
Fig. 1reporting of epidemiological studies were followed throughout (von
Elm et al., 2007).
3. Results
Forty-eight percent (n = 1,029) of smokers using NRT were male,
with a mean [standard deviation (SD)] age of 43.0 (15.56) years. The
percentages of participants in each social grade were as follows: AB
(12.0%, n= 259), C1 (22.0%, n= 475), C2 (21.8%, n= 470), D (18.1%,
n = 391) and E (26.1%, n = 563). The mean (SD) daily cigarette con-
sumption was 12.8 (8.56), with 22.1% (n = 476) reporting smoking a
cigarette within 5 minutes of wakening, 35.0% (n = 754) between 6
and 30 minutes afterwakening, 19.2% (n=413)within 31–60minutes
of wakening and 23.7% (n= 509) more than an hour after wakening.
3.1. Combination NRT
Eighty-three percent (n = 1,798) of those using NRT for smoking
reduction and/or temporary abstinence used only one NRT product,
whilst 16.7% (n = 360) used a combination of NRT products. The
most frequent combination being the patch plus one or more non-
transdermal product (see Fig. 1). After adjusting for socio-demographic
characteristics and time to ﬁrst cigarette of the day, those using a combi-
nation of NRT products had a higher odds of reporting a previous quit
attempt compared to those using only one product [72.2% (n = 257)
versus 66.1% (n= 1174)]. There was no association with motivation to
quit. Forty-four percent (n= 783) and 42.2% (n= 152) of those using
only one product and those using more than one product reported that
they were motivated to quit smoking within the next three months,
respectively. Those using more than one product had a higher cigarette
consumption than those using only the patch or only one non-
transdermal product (M = 14.2 [SD ± 10.30] versus M = 12.5
[SD ± 8.14]).
3.2. Amount of NRT used
Fig. 2a and b show the average times per day smokers used NRT.
Table 1 shows average cigarette consumption and motivation to quit
as a function of frequency of NRT use.cone gum, lozenges, nasal spray and inhalator 
.
Note: For (a) and (b) missing data: n=239; total sample 1919 out of a possible 2158; For (c) missing data: n=140; total sample 2018 out of a 
possible 2158
Fig. 2. (a) Frequency of NRT use perweek amongst those using at least one non-transdermal NRT product; (b) frequency ofNRT use perweek amongst those using only the nicotine patch;
and (c) length of NRT use amongst those using any product.
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least daily. Of these, 59.5% (n=223) reported that theyweremotivated
to quit smokingwithin the next 3 months; whilst only 31.8% (n=100)
of those using the nicotine patch less than daily reported similar moti-
vation. This difference was signiﬁcant (see Table 2). Those using the
patch daily had a lower cigarette consumption, albeit not quite signiﬁ-
cant, compared to those using it less regularly [13.7 (SD± 8.56) versus
12.4 (SD ± 8.61)].Table 1






within the next three
months %(n)
Frequency of non-transdermal NRT %(n)
Less than 3 times per day 12.8 (9.33) 35.3 (294)
At least 4 times per day 11.9 (7.31) 53.3 (211)
Frequency of the nicotine patch %(n)
Non-daily 13.7 (8.56) 31.8 (100)
Daily 12.4 (8.61) 54.4 (375)
Length of NRT use
Less than 1 week (n = 326) 13.1 (10.11) 52.8 (172)
1–6 weeks (n = 664) 12.2 (8.38) 55.3 (367)
6–12 weeks (n = 330) 12.0 (7.40) 43.9 (145)
More than 12 weeks (n = 698) 13.5 (8.52) 40.7 (192)
Note: NRT = nicotine replacement therapy; M = mean; SD = standard deviation.Amongst those using the non-transdermal NCPs, 32.2% (n = 396)
used them at least 4 times per day. These individuals had over twice
the odds of reporting that they were motivated to quit smoking than
those using non-transdermal NCPs less than 4 times per day [53.3%
(n=211) versus 35.3% (n= 294)]. Cigarette consumptionwas also sig-
niﬁcantly lower amongst those using NRT more than 4 times per day
[11.9 (SD ± 7.31) versus 12.8 (SD ± 9.33); see Table 2].3.3. Length of NRT use
Fig. 2c shows the length of time smokers had used NRT for. Only
34.6% reported having used NRT for more than 3 months. Table 1
shows the percentage of participants reportingmotivation to quit with-
in the next three months and average cigarette consumption as a func-
tion of length of NRT use. Use of NRT longer than 6 weeks and 12 weeks
was associated, respectively, with reduced motivation to quit and
increased cigarette consumption (see Table 1).4. Discussion
Those using a combination of NRT products had higher cigarette
consumption and similar motivation to quit compared with those
using only one NRT product. Frequency of NRT use was negatively asso-
ciated with cigarette consumption and positively associated with moti-
vation to stop. Use of NRT longer than 6 weeks was associated with
reduced motivation to quit, whilst NRT use longer than 12 weeks was
associated with increased cigarette consumption.
Table 2
Regression analysis of the association between combination NRT, amount of NRT used and length of use with motivation to quit and cigarette consumption.
Motivation to quit Cigarette consumption
OR 95% CI p β 95% CI P
Combination NRT 0.96 0.76 to 1.21 0.716 1.34 0.46 to 2.22 0.003
Amount of NRT used (patch)
Non-daily 1 1
Daily 3.18 2.30 to 4.40 b0.001 −1.13 −2.30 to 0.04 0.059
Amount of NRT used (non-transdermal)
Less than 3 times per day 1 1
Four or more times per day 2.09 1.63 to 2.67 b0.001 −0.86 −2.089 to−0.17 0.022
Length of NRT use ф
Up to 6 weeks 0.11 0.85 to 1.45 0.296
More than 6 weeks 0.49 0.37 to 0.64 b0.001
Up to 12 weeks −0.73 −0.76 to 0.31 0.156
More than 12 weeks 1.28 0.26 to−2.31 0.020
Note: NRT = nicotine replacement therapy. All analyseswere adjusted for age, gender, social grade and time to ﬁrst cigarette of the day. Associationswith cigarette consumptionwere also
adjusted for previous attempts to quit smoking; ф segmented regression identiﬁed a break point in the association between length of NRT use and cigarette consumption at 12 weeks and
motivation to quit at 6 weeks.
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tion NRT use amongst dual cigarette and NRT users not attempting
to quit. Less than 17% of participants reported using multiple NRT
products whilst concurrently smoking. This is much lower than the
previously reported prevalence of combined NRT use amongst those
attempting to quit (e.g. Johnson, Anderson, & Lockhart, 2014). This like-
ly reﬂects the cost of NRT and lack of professional support. Smokers
usingNRT for smoking reduction generally purchaseNRTover the coun-
ter (Hammond et al., 2008), whereas those smokers attempting to quit
often obtainNRTon prescription fromgeneral practitioners at a reduced
cost or for free.
Previous clinical trials have demonstrated that combination NRT
is more effective than the use of only one product amongst those
attempting to quit. Combination NRT has been to shown to increase
smoking abstinence rates, lead to higher salivary cotinine concentra-
tions and lower withdrawal scores (Stead et al., 2008). The failure to
ﬁnd a beneﬁt of combined NRT use in the current study may be due to
the cross-sectional nature of the data precluding any change in cigarette
consumption or motivation to quit. Those opting for multiple products
may have a priori been more nicotine dependent and less enthused
about stopping, and thus any increase in motivation and/or decrease
in consumption, unless excessive, would not be detected.
An alternative explanation is that smokers using a combination of
NRT products for smoking reduction do so sequentially rather than con-
currently (Beard, Vangeli, et al., 2012). Sequential use is unlikely to pre-
vent compensatory smoking since smokers cannot adequately replace
all the nicotine lost from their cigarettes. For this to be abated, complete
nicotine substitution through the concurrent use of multiple forms of
NRT is likely to be necessary. A ﬁnal explanation, which is supported
by the other ﬁndings in this paper, is that smokers were not using an
adequate amount of either NRT to produce a clinical beneﬁt, possibly
due to the lack of behavioural support at the population level.
Of interest, is that the majority of smokers failed to use non-
transdermal nicotine products as frequently as recommended (e.g. nic-
otine gum can be used up to 15 times per day) and only half of the
smokers reported having used NRT for longer than 6 weeks. This is con-
sistent with previous population-based studies looking at adherence to
nicotine-containing products (Shiffman et al., 2003), but is in contrast to
the clinical trials that reported high adherence to the NRT regimen
(Moore et al., 2009). Poor adherence may be a consequence of cost, in-
accurate beliefs about the safety of NRT or lack of knowledge regarding
the product's use.
The fact that those who used NRT frequently enough for a clinical
beneﬁt to have been expected had signiﬁcantly lower cigarette con-
sumption than those using NRT infrequently, suggests that the pooradherence may at least partially explain why, at the population level,
those using NRT for smoking reduction do not report signiﬁcantly
large declines in their cigarette consumption (Beard et al., 2014). How-
ever, declineswere still not in the region of those reported in the clinical
trials (i.e. over 50%). Although the true extent of reduction may be pre-
cluded by the cross-sectional nature of the study, it is possible that the
behavioural support offered by these trials also had a signiﬁcant impact
on outcomes. This assertion is supported by the previous ﬁnding that
even over a 6-month period, reductions in cigarette consumption at
the population level ranged from 1 to 2 cigarettes per day (Beard,
McNeill, et al., 2013).
Length of NRT use also appears to be an important factor. Up to three
months of use, there appears to be a decline, albeit not signiﬁcant, in
cigarette consumption. Following this point, there is an increase in cig-
arette intake per day. This might reﬂect the fact that those who use NRT
for longer are more nicotine dependent, although dependency was ad-
justed for in the analysis.Moreover, this ﬁnding of a non-linear relation-
ship between length of NRT use and cigarette consumption is consistent
with previous studies (Haustein et al., 2003; Moore et al., 2009). It may
be that over time, smokers enter a “maintenance phase” and therefore
cease reductions in their cigarette intake and/or start to believe that
they have failed in their attempts to cut down, with decreasing self-
efﬁcacy resulting in them abandoning attempts to reduce their intake.
Finally, although caution should be takenwhen interpreting the pos-
itive association between extent of use and motivation to quit, this
ﬁnding suggests that the “effectiveness” of NRT for smoking reduction
and/or temporary abstinence at the population level may be increased by
encouraging smokers to use NRT products more regularly. At the same
time, the ﬁnding that motivation to quit is lower following 6 weeks
of NRT use suggests that caution may be warranted regarding the long-
term use of nicotine-containing products during smoking reduction.
This is in contrast to previous research on the long-term use of NRT
for complete substitution of cigarettes. It is largely accepted that long-
term NRT use amongst smokers who have quit smoking could be
beneﬁcial (e.g. Agboola, McNeill, Coleman, & Bee, 2010). The premise
is that complete substitution with NRT could prevent relapse and that
the risks would be limited only to maintaining nicotine addiction
without the adverse consequences of continued tobacco consumption.
A similar beneﬁtmay not be expected amongst those partially substituting
their cigarettes for NRT as smokers are likely to enter a maintenance
phase when they become complacent with their smoking habit.
Reductions in cigarette consumption amongst dual users of NRT ciga-
rettes were found to subside over time in previous clinical trials
(Haustein et al., 2003; Moore et al., 2009). Similarly, if it is the case
that in the “real world” those who are more nicotine dependent
38 E. Beard et al. / Addictive Behaviors 40 (2015) 33–38use NRT for longer, one may expect that those using NRT for extended
periods of time will have higher cigarette consumption and lower odds
of a quit attempt due to selection bias.
In conclusion, these ﬁndings suggest that the association between
the use of NRT for smoking reduction and attempts to quit smoking
and cigarette consumption may at least be partially dependent on
extent of NRT use. Although this is the ﬁrst study to our knowledge
that has assessed extent of NRT use amongst those using NRT for
smoking reduction and/or temporary abstinence, it does suffer from
several limitations. First, care must be taken when making conclusions
about the effectiveness of NRT for smoking reduction and/or temporary
abstinence on the basis of this data alone. The cross-sectional analyses
mean that directional relationships cannot be determined. For example,
it might be the case that greater NRT use increases smokers' motivation
to quit, or that smokers who aremoremotivated to quit opt to usemore
NRT. Secondly, although reduced cigarette consumption is indicative of
a reduction in harm, future studies would beneﬁt from the inclusion of
biological measures of toxin intake.
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